APIDRA
Generic Name for APIDRA
Insulin glulisine (rDNA origin) 100 Units/mL; contains m-cresol.
Legal Classification:
Rx
Manufacturer of APIDRA
Sanofi-aventis
|
Indications for APIDRA
Type 1 diabetes (in adults and children) and type 2 diabetes (in adults).
Adults and Children:
<4yrs: not recommended. ≥4yrs: Give SC, either by injection or by external infusion pump. Rotate injection sites. SC inj: give 15 minutes before meal or within 20 minutes after starting meal; use with an intermediate or long-acting insulin. Or, may give by IV under medical supervision. Individualize; monitor and adjust as needed.
Contraindications for APIDRA
During episodes of hypoglycemia.
Warnings/Precautions for APIDRA
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, and management of hypoglycemia. Monitor glucose, potassium levels (esp. by IV route). May need to adjust dose during infection, illness, stress, trauma, pregnancy. May need lesser dose with renal or hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers.
Interactions for APIDRA
See literature. Potentiated by ACE inhibitors, antidiabetic agents, pramlintide, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics. Antagonized by corticosteroids, diuretics, sympathomimetics, glucagon, isoniazid, phenothiazines, somatropin, protease inhibitors, atypical antipsychotics, thyroid hormones, estrogens, progestogens. Variable effects with β-blockers, clonidine, lithium, alcohol. Do not mix with insulins other than NPH; draw insulin glulisine into syringe first, inject immediately after mixing. Do not dilute or mix with other insulins in pump.
Adverse Reactions for APIDRA
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, weight gain, peripheral edema.
How is APIDRA supplied?
Vial (10mL)—1
Cartridges (3mL)—5 (use with OptiClik)
Apidra SoloStar pen (3mL)—5 (prefilled, disposable inj device)
Related Disease:
Diabetes mellitus~hyperglycemic agents